Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | CDK4 | P11802 | 4/20 | 0.57 |
| ▸ | CCND1 | P24385 | 4/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1519806 | 1.00 | KMT2A (0.71) | KMT2ALMNACDK4CCND1MAPK1 | |
| SCHEMBL29420405 | 0.83 | KMT2A (1.00) | KMT2ALMNACDK4CCND1MAPK1 | |
| SCHEMBL1598786 | 0.83 | KMT2A (1.00) | KMT2ALMNACDK4CCND1MAPK1 | |
| SCHEMBL7349228 | 0.82 | LMNA (1.00) | KMT2ALMNACDK4CCND1MAPK1 | |
| Hydrochloric Acid SCHEMBL25303352 | 0.81 | KMT2A (0.96) | KMT2ALMNACDK4CCND1MAPK1 | |
| SCHEMBL30074152 | 0.81 | KMT2A (0.71) | KMT2ALMNACDK4CCND1MAPK1 | |
| SCHEMBL16286740 | 0.81 | KMT2A (0.71) | KMT2ALMNACDK4CCND1MAPK1 | |
| SCHEMBL9701534 | 0.81 | KMT2A (0.71) | KMT2ALMNACDK4CCND1MAPK1 | |
| SCHEMBL7876613 | 0.81 | KMT2A (0.65) | KMT2ALMNACDK4CCND1MAPK1 | |
| SCHEMBL3353214 | 0.77 | LMNA (0.44) | KMT2ALMNANTSR1HTR6POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122029161-A | Crystalline forms of PI3K inhibitors and uses thereof | 蝎子疗法股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| WO-2025229177-A1 | CRYSTALLINE FORMS OF AN N-SUBSTITUTED INDOLE DERIVATIVE | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-11-06 | — | — | WO | disclosed |
| CN-113474340-B | Novel isoindolinone substituted indoles and derivatives as RAS inhibitors | 勃林格殷格翰国际有限公司 | 2024-07-23 | — | — | CN | disclosed |
| US-11958850-B2 | Heteroaryl compounds for kinase inhibition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-04-16 | — | — | US | disclosed |
| CN-117143097-A | Beta-carbopol compound, preparation method thereof and application of beta-carbopol compound in resisting Alzheimer disease | 中国人民解放军北部战区总医院 | 2023-12-01 | — | — | CN | disclosed |
| US-20230277501-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-20230102829-A1 | Heteroaryl Compounds For Kinase Inhibition | ARIAD PHARMACEUTICALS, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20220370381-A1 | COMPOSITIONS AND METHODS FOR TREATING SEIZURE DISORDERS | ZOGENIX INTERNATIONAL LIMITED (GB) | 2022-11-24 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958850-B2 | Heteroaryl compounds for kinase inhibition | ERBB2, EGFR, ERBB3 | KMT2A 1587/4885LMNA 2843/4885CDK4 256/4885 |
| US-20230277501-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | GRIN2A, CHRNA2, SYNGR2 | KMT2A 140/4885LMNA 1805/4885CDK4 3670/4885 |
| US-20230102829-A1 | Heteroaryl Compounds For Kinase Inhibition | ERBB2, EGFR, ERBB3 | KMT2A 1587/4885LMNA 2843/4885CDK4 256/4885 |
| US-20220370381-A1 | COMPOSITIONS AND METHODS FOR TREATING SEIZURE DISORDERS | PSEN2, EPM2A, TPH2 | KMT2A 1680/4885LMNA 1258/4885CDK4 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.